Pricing Log in Create free account
Friday 6 November 2026 Export CATX’s income statement to Excel — free account

Perspective Therapeutics, Inc.

CATX Healthcare Medical Devices

Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024.

Revenue
−72.1%
EPS
+24.1%
Free cash flow
−66.1%
Total debt
−3.57%

Quarter to June 2026, against a year earlier

0.86 0.07 +8.86%
Market cap
$90.0M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
3/9
Altman Z
−0.59
Beneish M
0.59
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.62
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — 2 3 — —
Insider Ownership 21.23%

Capital & Financial Ratios $m

Size
Market Cap 89.99
Revenue ttm 0.41
Net income ttm (116.43)
Free cash flow ttm (121.19)
Net debt Q (235.34)
Valuation
P/E 0.00
Forward P/E (1.15) (negative: loss-making)
Price / sales 235.99 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.30
Financial health
Current ratio Q 6.61 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (412.08)
Growth
Revenue growth Q −72.07% (below 0%: shrinking)
Operating income growth Q −21.71% (below 0%: shrinking)
EPS, this year +30.93% (at or above 15%: strong)
EPS, next year A −3.46% (below 0%: weak)
Revenue, next year A −62.42% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +12.88%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −339×, against a ten-year median of 5.9×; over the ten years it ranged from −339× in 2026 to 520× in 2024.
P/S against its own 10 years 85.74%
10-year low 10-year high
P/B against its own 10 years 0.04%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 9 227 145 237
Receivables 1 0 0 0
Inventory — — — —
Other 5 — — —
17 231 148 242
2023 2024 2025 Q'26
Payables 7 10 21 29
ST’ Debt — — — —
Other 5 — — —
16 18 29 37

Compound Annual Growth %

10y 5y 3y
Sales (15.22%) (38.04%) (56.57%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 28.86% 25.16% 55.90%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.27 Actual −0.22

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY25 −0.30 −0.30 Met by 0.00
Q3 FY25 −0.33 −0.35 Miss by 0.02
Q1 FY26 −0.29 −0.25 Beat by 0.04
Q2 FY26 −0.27 −0.22 Beat by 0.05
Q3 FY26 −0.24 — Reports 9 November 2026

EPS $

Sep Dec Mar Jun Year
’26 — — (0.25) (0.22) —
’25 (0.35) (0.51) (0.25) (0.29) (1.40)
’24 (0.21) (0.59) (0.20) (0.18) (1.23)
’23 (0.30) (0.96) 0.00 (0.40) (1.70)
’22 (0.16) (0.10) (0.10) (0.15) (0.51)
’21 (0.10) (0.10) (0.06) (0.01) (0.33)
’20 (0.10) (0.10) (0.10) (0.02) (0.51)
Fiscal quarters ending in the months shown.

Revenue $m

Sep Dec Mar Jun Year
’26 — — 0 0 —
’25 0 0 0 0 1
’24 0 0 0 1 1
’23 2 0 0 1 1
’22 3 3 3 3 11
’21 2 2 3 3 10
’20 2 2 3 2 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Sep Dec Mar Jun Year
’26 — — (31) (21) —
’25 (16) (25) (22) (20) (82)
’24 3 (27) 14 (9) (18)
’23 (2) (9) (10) (8) (37)
’22 (2) (1) (1) (3) (8)
’21 0 (1) (2) (1) (3)
’20 (1) (1) (3) (1) (4)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Sep Dec Mar Jun Year
’26 — — (38) (35) —
’25 (18) (30) (26) (21) (95)
’24 (26) (41) 5 (10) (72)
’23 (2) (9) (10) (9) (38)
’22 (2) (1) (1) (3) (8)
’21 0 (1) (2) (1) (3)
’20 (1) (1) (3) (1) (4)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 5 5 6 7 10 10 11 1 1 1 0 (17.1%) 0 0 0 (30.9%)
Gross margin, % 2.70 17.60 31.10 41.66 52.93 50.94 42.76 100.00 100.00 100.00 100.00 +97.3 pt
EBT (5) (6) (7) (5) (3) (3) (7) (40) (80) (104) (117) +41.1%
EBT margin, % (98.78) (129.43) (113.12) (70.33) (35.60) (33.69) (67.36) (2,796.79) (5,531.43) (11,813.12) (28,710.02) (11,714.3) pt
Net income (5) (6) (7) (5) (3) (3) 0 (47) (79) (103) (116) +40.9%
Per share, $
Per share, $ Revenue 0.87 0.87 1.07 1.09 1.43 0.97 0.76 0.05 0.02 0.01 0.00 (37.8%)
Earnings (0.86) (1.12) (1.21) (0.77) (0.51) (0.33) (0.51) (1.70) (1.23) (1.40) (1.33) +5.6%
Cash flow (0.71) (1.04) (1.04) (0.75) (0.54) (0.27) (0.54) (1.38) (0.28) (1.12) (0.77) +5.2%
Capex (0.09) (0.10) (0.06) (0.06) (0.04) (0.04) (0.02) (0.04) (0.84) (0.17) (0.23) +7.9%
Free cash flow (0.79) (1.14) (1.10) (0.81) (0.58) (0.31) (0.56) (1.42) (1.12) (1.29) (1.00) +5.6%
Book value 2.98 1.93 0.91 1.15 0.85 6.49 0.00 2.81 4.51 2.80 2.68 (0.7%)
Shares, m 6 6 6 7 7 10 14 27 64 74 93 +33.4%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 100.36 72.22 40.70 37.58 38.83 82.43 4.07 74.84 141.35 229.62 235.99 82.2
P/B 29.18 32.43 47.92 35.79 65.68 12.29 0.72 1.43 0.71 0.98 0.30 22.7
EV/Sales 98.24 70.98 40.12 36.85 38.66 76.13 (1.09) 69.57 (13.60) 67.67 (339.40) 48.4
EV/FCF (74.15) (35.54) (25.32) (32.14) (61.87) (170.53) 1.47 (2.63) 0.27 (0.63) 1.15 (40.1)
Cash, $m
Cash, $m Operating cash flow (4) (6) (6) (5) (4) (3) (8) (37) (18) (82) (93) +40.4%
Capex 0 (1) 0 0 0 0 0 (1) (54) (13) (28) +44.0%
Free cash flow (4) (6) (6) (5) (4) (3) (8) (38) (72) (95) (121) +40.9%
Balance, $m
Balance, $m Working capital 13 9 4 6 4 66 50 1 213 120 205 +28.5%
Net debt (10) (6) (3) (5) (2) (63) (44) (8) (225) (143) (235) +34.2%
Shareholders’ equity 16 11 5 8 6 67 55 75 291 207 324 +32.5%
Returns, %
Returns, % ROA (22.98) (40.65) (68.05) (61.09) (38.15) (8.57) 0.00 (59.63) (36.12) (33.92) (33.14) (10.9) pt
ROIC (50.72) (84.41) (262.03) (139.50) (52.99) (52.50) 0.00 (37.84) (86.89) (111.14) (88.41) (60.4) pt
ROE (25.40) (45.72) (85.86) (81.12) (51.59) (9.27) 0.00 (71.65) (43.34) (41.44) (39.50) (16.0) pt
People
People Employees 41 36 38 43 53 61 66 119 140 166 — +16.8%
Revenue/emp, $m 0.12 0.13 0.16 0.17 0.18 0.16 0.16 0.01 0.01 0.01 — (29.0%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Perspective Therapeutics, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
APYX Apyx Medical Corporation $128.9M — (loss-making) — (loss-making) +8.95% (above 0%: growing) n/m +53.17% (above 0%: growing) 64.16% (4.07%) Compare
LUNG Pulmonx Corporation $111.5M — (loss-making) — (loss-making) +6.20% (above 0%: growing) n/m +61.33% (above 0%: growing) 76.19% (32.80%) Compare
ZOMDF Zomedica Corp. $95.4M — (loss-making) — (loss-making) +22.29% (above 0%: growing) n/m +32.51% (above 0%: growing) 61.06% (34.60%) Compare
CATX Perspective Therapeutics, Inc. $90.0M — (loss-making) — (loss-making) −72.07% (below 0%: shrinking) n/m −66.09% (below 0%: shrinking) 100.00% (36,120.99%)
NYXH Nyxoah SA $82.6M — (loss-making) — (loss-making) +486.62% (above 0%: growing) n/m +4.01% (above 0%: growing) 59.73% (268.25%) Compare
SERA Sera Prognostics, Inc. $82.1M — (loss-making) — (loss-making) +162.50% (above 0%: growing) n/m −12.79% (below 0%: shrinking) 0.00% (21,159.52%) Compare
LUCD Lucid Diagnostics Inc. $79.3M — (loss-making) — (loss-making) +26.74% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 1.97% (868.45%) Compare
OM Outset Medical, Inc. $77.0M — (loss-making) — (loss-making) +14.15% (above 0%: growing) n/m −61.85% (below 0%: shrinking) 40.69% (36.52%) Compare
HYPR Hyperfine, Inc. $72.7M — (loss-making) — (loss-making) +44.81% (above 0%: growing) n/m +13.43% (above 0%: growing) 50.72% (216.93%) Compare
Median of peers $82.3M — — +24.52% — +8.72% 55.23% (126.72%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 16 April 2026

Ownership

Directors and executive officers, together 2.99%
Commodore Capital LP8 10.72%
Lantheus Alpha Therapy, LLC7 10.24%
TCG9 6.94%
Qatar Investment Authority10 6.20%
Avidity Partners Management LP11 5.31%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Perspective Therapeutics, Inc. (CATX) Latest News

6 Nov

Impact 3 · · GlobeNewswire

5 Nov

Impact 3 · · GlobeNewswire

23 Oct

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

8 Oct

Impact 4 · · GlobeNewswire

7 Oct

Impact 3 · · GlobeNewswire

2 Oct

Impact 3 ·

14 Sep

Impact 4 ·

11 Aug

Impact 4 ·

10 Aug

Impact 3 ·

28 Jul

Impact 4 ·

17 Jul

Impact 3 ·

5 Jul

Impact 4 ·

3 Jun

Impact 3 · · Proactive Investors
Impact 3 · · GlobeNewswire

21 May

Impact 3 · · GlobeNewswire

18 May

Impact 3 · · GlobeNewswire

11 May

Impact 4 · · GlobeNewswire

20 Apr

Impact 4 ·

17 Mar

Impact 3 · · GlobeNewswire

16 Mar

Impact 4 · · GlobeNewswire

17 Feb

Impact 4 · · Insider Monkey

4 Feb

Impact 4 · · Simply Wall St.

2 Feb

Impact 4 · · GlobeNewswire

1 Feb

Impact 4 · · Simply Wall St.

12 Jan

Impact 3 · · GlobeNewswire

9 Jan

Impact 4 · · GlobeNewswire

18 Dec

Impact 3 · · GlobeNewswire

4 Dec

Impact 4 · · GlobeNewswire

20 Nov

Impact 3 · · GlobeNewswire
stockrow.com/CATX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com